Mục lục
Tóm tắt
Background: Little is known about gender differences of coronary heart disease patients undergoing percutaneous coronary intervention (PCI) in low-and middle-income nations, despite its rapid uptake across Asia. Objective: to report on gender clinical characteristics and in-hospital outcomes for patients undergoing percutaneous coronary intervention at a leading cardiac centre in Vietnam. Methods: Information on characteristics, treatments, and outcomes of patients undergoing percutaneous coronary intervention was collected into the first registry. Subgroup analysis was conducted to explore gender differences. Results: Between September 2017 and May 2018, 1,022 patients undergoing percutaneous coronary intervention were recruited from a total of 1,041 procedures. The mean age was 68.3 years, and two thirds were male. Female patients were older, lower educational level, monthly income and involved with more manual jobs than male (p<0.0001). Despite having less serve clinical presentations, female tent to have more comorbidities and a higher incidence of major bleeding than males (p<0.05). Conclusions: the findings may contribute to evaluating PCI-related practices, identifying the gaps in sex-specific care for cardiovascular health, and potentially developing appropriate treatment guidelines.
INTRODUCTION
Percutaneous coronary intervention (PCI) has been demonstrated to be an effective treatment for coronary heart disease (CHD) worldwide since its inception in the late 1970s1,2. The procedure has become more widely used in Asia, where CHD was the leading cause of death (approximately 16.2% of all deaths in 2016)3,4, with around one million PCIs undertaken in 2016 alone5. Notwithstanding the apparent benefits of PCI, post-procedural cardiac complications remain a concern, including death, myocardial infarction (MI) and bleeding6,7.
Accumulating data in the USA and Europe have shown that the occurrence of these adverse cardiac events differed according to many factors, including gender6,8,9. In Asia, cardiac registries in some high-income countries have also reported similar findings10,11, while relevant data remains limited in lower-and middle-income countries. Additionally, most medical care provided for CHD patients in Asian countries is based on the European or North American guidelines developed from large domestic registries12-14. It is not clear whether the non-Asian data reflects the Asian experience, nor whether the guidelines are well suited to the Asian population. Thus, data from real-world practice in less developed countries are very important to establish current benchmarks and determine appropriate management and preventive strategies for these populations.
Vietnam is a middle-income nation in South-East Asia, where PCI has been widely used in modern cardiac based treatments for CHD, the second leading cause of death15. The aim of this paper is to provide insights concerning the gender differences in clinical characteristics and in-hospital outcomes of patients undergoing PCI in Vietnam based on the first PCI registry conducted at a leading cardiac hospital in Vietnam.
METHODS
Participants, time and location of study
Participants were patients underwent percutaneous coronary intervention at the Vietnam National Heart Institute (VNHI), Hanoi, Vietnam during September 2017-May 2018. The study was conducted at VNHI, the leading cardiac centre nationwide, where the highest quality of healthcare services are provided for around 17,000 cardiovascular inpatients and 80,000 out-patients annually16.
It was a pilot registry study. Potential participants were patients who underwent PCI at VNHI during the study period and met the following criteria: Vietnamese residents aged 18 years and over; Had at least one active phone contact number; and able to communicate, understand the information sheet and did not opt-out of future follow-ups by the time of discharge. There were no exclusion criteria.
Data collection
This single-centre, hospital-based registry adapted the data collection forms currently used in the Victorian Cardiac Outcomes and Melbourne Interventional Group registries, Australia17,18. Information on demographic, clinical and procedural information, and outcomes of patients who underwent PCI was recorded on standardised data abstraction forms with standard definitions for all fields. Information was collected via patient interviews, extracting medical records, reading the PCR disks.
Information collection
Patient characteristics
Information on participant demographics, medical history, cardiovascular risk factors (diabetes, hypertension, dyslipidemia, cerebrovascular disease), clinical symptoms and presentation (acute coronary syndrome (ACS), cardiogenic shock, cardiac arrest), left ventricular ejection fraction, and pre-procedural renal status was collected via both patient interviews and medical records.
Procedures and medications
The strategy for the specific coronary intervention (e.g. choice of stent, medication) was at the discretion of the interventionists. Injured lesion segments were coded following the classification of the Syntax Score19 and guidelines for the lesion type of American College of Cardiology/ American Heart Association (ACC/AHA)20. A procedure was considered successful if there was a residual stenosis of less than 10% following coronary stenting and the rate of coronary blood perfusion of Thrombosis in Myocardial Infarction 2 or 3 flow. Pre and post procedural medical therapies such as oral antiplatelet, aspirin, anti-thrombin, and glycoprotein IIb/IIIa inhibitors were evaluated according to the 2016 ACC/AHA guidelines21. Medications and procedural data were obtained by extracting medical records and reading secured procedural disks.
Clinical outcomes
Medical records were extracted to document in-hospital complications including death, new or recurrent MI, cardiogenic shock, bleeding, post-procedural renal impairment, new requirement for dialysis, unplanned target vessel revascularisation (revascularisation for the previously cured coronary artery) by PCI or coronary artery bypass grafts (CABG), stent thrombosis, and stroke.
Statistical analysis
Data on demographic, clinical, procedures and outcomes were presented as numbers (and percentages) for categorical variables, and means (with standard deviations) for continuous variables. Descriptive statistics were used to summarise characteristics of the study participants. Fisher exact or Chi-square tests were undertaken to compare categorical variables, and Student’s t tests or analysis of variance (ANOVA) were applied to compare continuous variables. All p-values were two-tailed with significance defined as p ≤0.05. All statistical analyses were performed using the SPSS statistical package (SPSS Version 20.0 for Windows; SPSS Inc., Chicago, IL).
Research ethics
The study protocol was approved by the Curtin University Ethics Committee before the commencement of data collection (HRE 2017-0378). Patients had the right to opt out of the study without impacting on their care. Data collection was conducted by a team of specifically trained local investigators at VNHI.
RESULTS
Patient characteristics by gender
Table 1. Clinical characteristics (n= 1022)
Female | Male | P value* | |
Patients | 326 (31.9) | 696 (68.1) | _ |
Age (years), mean ± SD | 70.9 ± 9.4 | 67.0 ± 10.5 | <0.0001 † |
Kinh people | 321 (98.5) | 667 (95.8) | 0.045 |
From provinces outside Hanoi | 233 (71.5) | 563 (80.9) | 0.001 |
Education Primary school and lower Secondary school High school College and higher | 47 (14.4) 122 (37.4) 40 (12.3) 117 (35.9) | 36 (5.2) 245 (35.2) 124 (17.8) 291 (41.8) | <0.0001 |
Current/ past occupation Officer worker Manual worker Farmer Tradesperson Others | 120 (36.8) 67 (20.6) 107 (32.8) 17 (5.2) 15 (4.6) | 269 (38.6) 96 (13.8) 148 (21.3) 47 (6.8) 136 (19.5) | <0.0001 |
Poverty a | 19 (5.8) | 25 (3.6) | 0.175 |
Low income b | 279 (85.6) | 483 (69.4) | <0.0001 |
Body mass index (kg/m2) Low (<18.5) Normal (18.5- 22.9) High (≥ 23.0) | 38 (11.7) 178 (54.6) 110 (33.7) | 69 (9.9) 340 (48.9) 287 (41.2) | 0.071 |
Data are presented as n (%), otherwise specified.
* Comparing female and male subjects; a Obtained certificates of poor and near poor household; b Individual monthly income < 216 USD with the exchange rate of 23.150 VND; c Creatinine > 200µmol/L.
A total of 1,022 patients were enrolled into the registry. Of these, 19 patients had a second PCI, meaning a total of 1,041 procedures, treating 1,276 lesions.
Demographics and clinical characteristics of participants are summarized in Table 1. Two-thirds of the study population were male. The participants’ mean age (±SD) was 68.3 years (10.3) and females were approximately 4 years older than men (p<0.0001). Compared with males, females had a lower education level, monthly income and were more likely to do manual work (p<0.0001).
Figure 1. Risk factors of study participants
Additionally, females also had a higher prevalence of risk factors such as hypertension, diabetes, and hyperlipidaemia (p<0.05) with the exception of current smoking and previous PCI (p<0.05) compared to males (Figure 1).
Lesion, procedural characteristics and medications prior to PCI
Table 2. Lesion, procedural characteristics and medications prior to PCI (n= 1276*)
Female (n=406) | Male (n=870) | P value | |
Lesions | 406 (31.8) | 870 (68.2) | _ |
Percutaneous entry location | |||
Radial | 263 (79.2) | 561 (79.1) | >0.999 |
Femoral | 69 (20.8) | 148 (20.9) | |
Target vessel | |||
Left main | 29 (7.1) | 123 (14.2) | <0.0001 |
Left anterior descending | 208 (51.2) | 387 (44.5) | 0.030 |
Right coronary | 118 (29.1) | 288 (33.1) | 0.164 |
Circumflex | 80 (19.7) | 191 (22.0) | 0.394 |
PCI with 2 lesions | 69 (17.0) | 149 (17.1) | >0.999 |
Type B2 and C lesions | 381 (93.8) | 821 (94.5) | 0.745 |
Chronic total occlusion | 10 (2.5) | 51 (5.9) | 0.012 |
Restenotic lesions | 11 (2.7) | 53 (6.1) | 0.014 |
Stents used for each lesion | |||
≤ 1 | 271 (66.7) | 517 (59.5) | 0.015 |
≥ 2 | 135 (33.3) | 352 (40.5) | |
Mean (± SD) | 1.42 (± 0.64) | 1.54 (± 0.74) | 0.002 |
Stent length > 20mm | 375 (95.2) | 806 (96.2) | 0.502 |
Mean stent length (± SD) | 34.5 (± 8.9) | 34.7 (± 8.7) | 0.656 |
Angiographic success | 405 (99.8) | 862 (99.2) | 0.448 |
Drug-eluting stent use | 394 (97.3) | 837 (97.1) | 0.998 |
Balloon only | 11 (2.7) | 25 (2.9) | |
Guidance of IVUS | 13 (3.2) | 33 (3.8) | 0.654 |
Medications | |||
Fibrinolytic therapy | 1 (50.0) | 1 (50.0) | 0.536 |
Glycorprotein IIb/ IIIa | |||
Antithrombin therapy | 111 (34.3) | 266 (37.5) | 0.227 |
Ticagrelor | 35 (10.5) | 141 (19.9) | <0.0001 |
Clopidogrel/ Ticlopidine | 284 (85.5) | 549 (77.4) | 0.003 |
Aspirin | 320 (96.4) | 695 (98.0) | 0.172 |
*missing information of one lesion
Data are presented as n (%), unless specified. IVUS: Intravascular Ultrasound
There were 1,276 lesions which required subsequent treatment within 1041 procedures (Table 2).
Compared with females, males were more likely to have disease in the left main coronary artery, chronic total occlusions, stent restenosis, and ≥ 2 stents per lesion (p<0.05). They tended to receive ticagrelor, while their female counterparts were relatively more likely to be prescribed with clopidogrel prior to PCI (both p<0.05).
In-hospital outcomes and medications post PCI
Table 3. In-hospital outcomes and medications post PCI (n= 1041)
Outcomes | Female (n=332) | Male (n=709) | p |
New renal impairment | 11 (3.3) | 22 (3.1) | >0.999 |
New dialysis | 1 (0.3) | 8 (1.1) | 0.286 |
Cardiogenic shock | 1 (0.3) | 3 (0.4) | >0.999 |
New/ recurrent MI | 2 (0.6) | 1 (0.1) | 0.24 |
Unplanned PCI | 1 (0.3) | 1 (0.1) | >0.999 |
Stent thrombosis | 2 (0.6) | 0 (0.0) | 0.102 |
Major bleeding | 12 (3.6) | 9 (1.3) | 0.023 |
Stroke | 1 (0.3) | 4 (0.6) | >0.999 |
Death | 3 (0.9) | 3 (0.4) | 0.39 |
Hospital length (day), median | 2.0 | 2.0 | 0.69 |
Hospital length > 2 days | 34.3 | 32.4 | 0.59 |
Medications | |||
Aspirin | 329 (99.7) | 704 (99.7) | >0.999 |
Clopidogrel/ Ticlopidine | 290 (87.8) | 545 (77.2) | <0.0001 |
Ticagrelor | 40 (12.2) | 161 (22.9) | <0.0001 |
Beta Blockers | 138 (41.8) | 259 (37.0) | 0.125 |
Angiotensin-receptor blockers | 308 (93.6) | 644 (91.6) | 0.317 |
Statin | 330 (100.0) | 703 (99.6) | 0.556 |
Other lipid lowering therapy | 3 (0.9) | 0 (0.0) | 0.032 |
Oral anticoagulation therapy | 2 (0.6) | 2 (0.3) | 0.956 |
Data are presented as n (%), unless specified.
Major bleeding rate was higher in females than males (p<0.05). Ticagrelor was commonly used in males, while clopidogrel was frequently prescribed in the latter (p<0.0001).
DISCUSSION
This study was the first to provide gender differences in several demographic and socioeconomic factors, clinical presentation and treatment which may be potentially important in the design of optimal care in developing settings.
Patterns of gender differences in demographic, socioeconomic and clinical factors are consistent with prior research 8,22,23. For example, our study showed females receiving PCI accounted for nearly one-third of total participants, those females were generally older and had more comorbidities than males. In our data, the female to male ratio was 0.47, which contrasts with the general Vietnamese population group age 64 and above which has a female to male ratio of 1.624. This lower incidence of PCI in females might be explained by the relatively lower priority in families of females compared to males in Vietnamese culture. This may be exacerbated by the high cost requirement of the procedure itself and other hospital treatments in the national centre as VNHI. More males were transferred from other provinces to VNHI for PCI in comparison to females (p= 0.001), which may support this theory. Additionally, presenting females were on average 4 years older than males (p< 0.0001). The protective impact of oestrogen in females in delaying the onset of cardiovascular disease is likely to be part of the explanation25. The 4-year age gap also partly explains more comorbidities seen in females such as hypertension, diabetes and hyperlipidaemia in our study. The Global Registry of Acute Coronary Events (GRACE) indicated that, in the group of patients undergoing cardiac intervention, females had higher rates of diabetes, hypertension, but were less likely to smoke9. Data from several systematic review with meta-analysis also confirmed that females with cardiovascular risk factors were more likely to have incident CHD than males26,27.
Regarding clinical presentations, in general, females receiving PCI had lower procedural risks relative to males. Results from the GRACE registry indicated that females were more likely to have normal/mild diseases and less likely to have injured lesion in left main vessel9. Although this is not direct comparison as GRACE contained patients undergoing catheterization only, our finding is in line with that result. Similarly, a nationwide study in patients undergoing PCI in Korea reported that males had more chronic lesions in left main vessel, and required a higher number of stents than females23. Data from a national cardiovascular registry in America also revealed that females had a lower risk of angiographic features, and needed shorter stents8.
In term of in-hospital outcomes, previous studies have largely reported that, females were at a higher risk of having complications or worse PCI-specific outcomes, e.g. death, bleeding or cardiogenic shock than males8,22,28. Likewise, females in our study were more likely to have major bleeding relative to males. It is possible that females were older, had a higher prevalence of coronary risk factors, and a smaller body size as well as smaller arteries than males at the time of PCI procedure8,23. It is also worth noting that most current PCI-based devices and medication therapies have been designed relatively equally between males and females, without a specific gender indication29. Thus, more focused efforts should be taken to prevent and reduce bleeding complications in female patients with PCI.
STUDY LIMITATIONS
There are some limitations to our study. Despite data was collected at the national and biggest cardiac interventional centre in Vietnam, our findings might not be representative of the whole nation, particularly in terms of lesion type and uptake of cutting-edge interventions as VNHI is a single centre only. Furthermore, some uncertainties and recall errors of the patients in self-reporting the socioeconomic status as well as cardiovascular risk factors might occur, which can contribute to the differences observed. Additional dedicated studies should be conducted to provide more overall views of PCI practices in Vietnam.
CONCLUSION
Our study based on the first Vietnamese PCI registry provides an opportunity to understand insights of gender differences in clinical characteristics and in-hospital outcomes of the patients undergoing PCI in Vietnam. The findings may contribute to evaluating PCI-related practices, identifying the gaps in sex-specific care for cardiovascular health, and potentially developing appropriate treatment guidelines.
Tài liệu tham khảo
1. Soran, O., Manchanda, A. & Schueler, S. Percutaneous coronary intervention versus coronary artery bypass surgery in multivessel disease: a current perspective. Interact Cardiovasc Thorac Surg 8, 666-671 (2009). https://doi.org/10.1510/icvts.2008.195644
2. Movahed, M. R., Ramaraj, R., Jamal, M. M. & Hashemzadeh, M. Nationwide trends in the utilisation of percutaneous coronary intervention (PCI) in the United States of America based on gender and ethnicities. EuroIntervention 5, 343-348 (2009).
3. World Health Organization. (2017).
4. Thomas, H. et al. Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control. Glob Heart 13, 143-163 (2018). https://doi.org/10.1016/j.gheart.2018.09.511
5. Gao R. The evolution of percutaneous coronary intervention in Asia: in celebration of the 40th anniversary of percutaneous transluminal coronary angioplasty. Asia Intervention 3, 95-96 (2017). https://doi.org/DOI: 10.4244/AIJV3I2A18
6. Ricci, B. et al. Primary percutaneous coronary intervention in octogenarians. Int J Cardiol 222, 1129-1135 (2016). https://doi.org/10.1016/j.ijcard.2016.07.204
7. Han, S. et al. Trends, Characteristics, and Clinical Outcomes of Patients Undergoing Percutaneous Coronary Intervention in Korea between 2011 and 2015. Korean Circ J 48, 310-321 (2018). https://doi.org/10.4070/kcj.2017.0359
8. Akhter, N. et al. Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Am. Heart J. 157, 141-148 (2009). https://doi.org/10.1016/j.ahj.2008.08.012
9. Dey, S. et al. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart 95, 20-26 (2009). https://doi.org/10.1136/hrt.2007.138537
10. Kaneko, H. et al. Impact of aging on the clinical outcomes of Japanese patients with coronary artery disease after percutaneous coronary intervention. Heart and Vessels 29, 156-164 (2014). https://doi.org/10.1007/s00380-013-0339-9
11. Li, Y. J. et al. Clinical characteristics and mid-term outcomes of acute myocardial infarction patients with prior cerebrovascular disease in an Asian population: Lessons from the Korea Acute Myocardial Infarction Registry. Clin Exp Pharmacol Physiol 37, 581-586 (2010). https://doi.org/10.1111/j.1440-1681.2010.05363.x
12. Hasdai, D. et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 23, 1190-1201 (2002).
13. Budaj, A. et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 146, 999-1006 (2003). https://doi.org/10.1016/S0002-8703(03)00509-X
14. Asia-Pacific ACS Medical Management Working Group et al. Challenges and solutions in medically managed ACS in the Asia-Pacific region: expert recommendations from the Asia-Pacific ACS Medical Management Working Group. Int J Cardiol 183, 63-75 (2015). https://doi.org/10.1016/j.ijcard.2014.11.195
15. World Health Rankings. Vol. 2019 (2017).
16. Vietnam National Heart Institue. Vol. 2019 (2017).
17. Yeoh, J. et al. Evolution of Australian Percutaneous Coronary Intervention (from the Melbourne Interventional Group [MIG] Registry). Am. J. Cardiol. 120, 47-54 (2017). https://doi.org/10.1016/j.amjcard.2017.03.258
18. Stub, D. et al. The Establishment of the Victorian Cardiac Outcomes Registry (VCOR): Monitoring and Optimising Outcomes for Cardiac Patients in Victoria. Heart Lung Circ 27, 451-463 (2018). https://doi.org/10.1016/j.hlc.2017.07.013
19. Syntax score working group. Vol. 2019 (2019).
20. Levine, G. N. et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 133, 1135-1147 (2016). https://doi.org/10.1161/CIR.0000000000000336
21. Levine GN et al. Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guidelineon Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 134, e192-194 (2016). https://doi.org/10.1161/CIR.0000000000000452
22. Al-Fiadh, A. H. et al. Contemporary outcomes in women undergoing percutaneous coronary intervention for acute coronary syndromes. Int J Cardiol 151, 195-199 (2011). https://doi.org/10.1016/j.ijcard.2010.05.018
23. Park, D. W. et al. Sex difference in clinical outcomes after percutaneous coronary intervention in Korean population. Am Heart J 167, 743-752 (2014). https://doi.org/10.1016/j.ahj.2013.12.027
24. Vietnam Population. (2019).
25. Spary, E. J., Maqbool, A. & Batten, T. F. Oestrogen receptors in the central nervous system and evidence for their role in the control of cardiovascular function. J Chem Neuroanat 38, 185-196 (2009). https://doi.org/10.1016/j.jchemneu.2009.05.008
26. Peters, S. A., Singhateh, Y., Mackay, D., Huxley, R. R. & Woodward, M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. Atherosclerosis 248, 123-131 (2016). https://doi.org/10.1016/j.atherosclerosis.2016.03.016
27. Peters, S. A., Huxley, R. R. & Woodward, M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57, 1542-1551 (2014). https://doi.org/10.1007/s00125-014-3260-6
28. Chua, S. K. et al. Gender and Age Differences in Short- and Long-Term Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Acta Cardiol Sin 30, 274-283 (2014).
29. Lansky, A. J. et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women - A statement for healthcare professionals from the American Heart Association. Circulation 111, 940-953 (2005). https://doi.org/10.1161/01.Cir.0000155337.50423.C9

công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International . p>
Bản quyền (c) 2023 Tạp chí Khoa học và Công nghệ Y Dược